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Background: Determinants of hospitalisation, inten-
sive care unit (ICU) admission and death are still 
unclear for COVID-19. Few studies have adjusted for 
confounding for different clinical outcomes including 
all reported cases within a country. Aim: We used rou-
tine surveillance data from Portugal to identify risk fac-
tors for severe COVID-19 outcomes, and to support risk 
stratification, public health interventions, and plan-
ning of healthcare resources. Methods: We conducted 
a retrospective cohort study including 20,293 labora-
tory-confirmed cases of COVID-19 reported between 1 
March and 28 April 2020 through the national epide-
miological surveillance system. We calculated abso-
lute risk, relative risk (RR) and adjusted relative risk 
(aRR) to identify demographic and clinical factors 
associated with hospitalisation, ICU admission and 
death using Poisson regressions. Results: Increasing 
age (≥ 60 years) was the major determinant for all 
outcomes. Age ≥ 90 years was the strongest determi-
nant of hospital admission (aRR: 6.1), and 70–79 years 
for ICU (aRR: 10.4). Comorbidities of cardiovascular, 
immunodeficiency, kidney and lung disease (aRR: 4.3, 
2.8, 2.4, 2.0, respectively) had stronger associations 
with ICU admission, while for death they were kidney, 
cardiovascular and chronic neurological disease (aRR: 
2.9, 2.6, 2.0). Conclusions: Older age was the strong-
est risk factor for all severe outcomes. These findings 
from the early stages of the COVID-19 pandemic sup-
port risk-stratified public health measures that should 
prioritise protecting older people. Epidemiological 
scenarios and clinical guidelines should consider 
this, even though under-ascertainment should also be 
considered.
Introduction
Previous studies of clinical outcomes of coronavi-
rus disease (COVID-19) in China [1], Italy [2,3] and 
the United States (US) [4] have described risk fac-
tors for poorer clinical outcomes, including age, sex 
and comorbidities without adjusting for confounding. 
Identifying these determinants and their isolated risk 
can help inform health policy on risk stratification and 
implementation of public health measures, but also 
improve epidemiological scenarios and forecasts on 
the needed healthcare resources.
Other studies on risk factors for clinical outcomes 
of COVID-19 have included small series of patients, 
mostly among those hospitalised with severe disease 
[5-7], making it difficult to produce reliable estimates 
for specific risk factors in the general population.
There is still uncertainty about the contribution of 
each factor for hospitalisation, intensive care unit 
(ICU) admission and death in the general population, 
as only a few studies conducted multivariable analysis 
to account for confounding [8-10]. One study of labo-
ratory-confirmed COVID-19 cases in New York City, US, 
found an increased risk of hospitalisation for those 
aged 65 years and older when compared with those 
19–44 years [8]. A large cross-sectional survey in the 
United Kingdom (UK) describing 16,749 patients hospi-
talised with COVID-19 showed a higher risk of death for 
patients with increasing age, cardiovascular, pulmo-
nary or kidney disease, as well as malignancy, demen-
tia and obesity [9]. The largest cohort study to date (as 
at May 2020), the OpenSAFELY Collaborative study [10], 
was conducted in the UK and included 17 million adult 
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patients under the National Health Service (NHS). This 
study found that being a man, being older, and living 
in a more socioeconomically deprived community, as 
well as having uncontrolled diabetes, severe asthma, 
or other comorbidities were relevant risk factors for 
death by COVID-19.
High quality data on population level risk factors for 
poor outcomes of COVID-19 is needed to inform pub-
lic health policy and preparedness. Compared with 
several other European countries, in March and April 
2020, Portugal had a high estimated case ascertain-
ment, ranging from 22% (95% confidence interval (CI): 
18–39) [11] to 36.6% (95% CI: 29.5–45.7) [12], and it 
had a high testing rate in mid-May [13], despite having 
lower transmission levels, lower case fatality rate (CFR) 
and lower test positivity rates [14].
We aimed to further understand COVID-19 risk factors 
for three different outcomes – hospitalisation, ICU 
admission and death – in order to better support risk 
stratification, clinical and public health interventions 
and healthcare resource planning in Portugal.
Methods
Study design and data sources
We conducted a retrospective cohort study including 
all reported confirmed cases of COVID-19 in Portugal 
(n = 20,293) during the first 2 months of the pandemic 
Figure 1
Illustration of assumptions included in the model for associations between exposures of interest and confounding variables
Region
Healthcare services (practices and capacity)
Comorbidities
Exposure Ancestor of exposure
and outcome






ICU: intensive care unit.
The directed acrylic graph was generated using the R package DAGggity [15].
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(from 1 March to 28 April 2020). Outcomes measured 
were hospitalisation, ICU admission and death. We cal-
culated absolute risk, relative risk (RR) and adjusted 
relative risk (aRR) for age, sex, comorbidities and 
region of occurrence using Poisson regression.
We obtained anonymised data from the Portuguese 
Directorate-General of Health (DGS), including all con-
firmed cases of COVID-19 notified to the national epi-
demiological surveillance system (Sistema Nacional 
de Vigilância Epidemiológica, SINAVE). SINAVEmed is 
an electronic platform that includes information about 
clinical findings and comorbidities; clinicians are 
obliged by law to notify all suspected and confirmed 
cases of COVID-19. Notifications trigger an epidemio-
logical investigation by the local public health services, 
where a public health physician (health authority in 
the area of residence of the case) validates the case. 
At a later stage, the regional public health department 
and, finally, DGS conduct a final validation of case 
information.
Case definitions
A confirmed case of COVID-19 is defined as anyone with 
positive result for severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) RNA by RT-PCR in naso-
pharyngeal and/or oropharyngeal specimens regard-
less of clinical or epidemiological criteria. However, 
if these criteria were present, the likelihood of being 
tested and confirmed was higher.
Table 1
Association between geodemographic factors, comorbidities and hospitalisations among COVID-19 cases, Portugal, 1 












RR 95% CI p value aRR 95% CI p value
Sex
Women 10,949 1,416 12.9 Ref.
Men 7,721 1,556 20.2 1.6 1.5–1.7 < 0.001 1.4 1.4–1.5 < 0.001
Age (years)
0–49 9,055 462 5.1 Ref.
50–59 3,325 336 10.1 2.0 1.7–2.3 < 0.001 1.9 1.7–2.2 < 0.001
60–69 2,233 491 22.0 4.3 3.8–4.9 < 0.001 3.7 3.3–4.1 < 0.001
70–79 1,653 659 39.9 7.8 7.0–8.7 < 0.001 5.7 5.1–6.4 < 0.001
80–89 1,678 747 44.5 8.7 7.9–9.7 < 0.001 6.4 5.8–7.2 < 0.001
 ≥ 90 726 277 38.2 7.5 6.6–8.6 < 0.001 6.1 5.4–7-0 < 0.001
Regionc
North 11,090 1,453 13.1 Ref.
Acores 48 14 29.2 2.2 1.4–3.5 0.001 2.7 1.8–4.2 < 0.001
Alentejo 370 54 14.6 1.1 0.9–1.4 0.403 1.3 1.0–1.6 0.033
Algarve 462 92 19.9 1.5 1.3–1.8 < 0.001 1.7 1.4–2.0 < 0.001
Center 2,651 510 19.2 1.5 1.3–1.6 < 0.001 1.2 1.1–1.3 < 0.001
Lisbon and Tagus Valley 3,951 827 20.9 1.6 1.5–1.7 < 0.001 1.6 1.5–1.7 < 0.001
Madeira 87 15 17.2 1.3 0.8–2.1 0.255 2.0 1.4–3.0 0.001
Comorbidities
Asthma 258 26 10.1 0.6 0.4–0.9 0.01 0.9 0.6–1.2 0.356
Cancer 579 292 50.4 3.4 3.1–3.7 < 0.001 1.4 1.3–1.6 < 0.001
Cardiovascular disease 52 49 94.2 6.0 5.6–6.5 < 0.001 1.8 1.5–2.2 < 0.001
Diabetes 1,057 496 46.9 3.3 3.1–3.6 < 0.001 1.4 1.3–1.5 < 0.001
Immunodeficiencies 99 43 43.4 2.8 2.1–3.5 < 0.001 1.8 1.4–2.3 < 0.001
Kidney disease 382 273 71.5 4.8 4.5–5.2 < 0.001 1.6 1.4–1.7 < 0.001
Liver disease 102 64 62.7 4.0 3.4–4.7 < 0.001 1.5 1.2–2.0 < 0.001
Lung disease 637 292 45.8 3.1 2.8–3.4 < 0.001 1.4 1.3–1.5 < 0.001
Haematological disease 202 131 64.9 4.2 3.8–4.7 < 0.001 1.4 1.2–1.6 < 0.001
Neurological disease 733 476 64.9 4.7 4.4–5.0 < 0.001 1.8 1.7–2.0 < 0.001
aRR: adjusted risk reduction; CI: confidence interval; COVID-19: coronavirus disease; Ref.: reference; RR: risk reduction.
a Only 18,670 people included in the study had a known hospital admission status.
b Hospitalisations refer to those in the general ward.
c The total for the regions was 18,659 cases; 11 cases were missing.
The area under the ROC curve (AUC) was 0.823 (asymptotic 95% CI: 0.814–0.831).
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Up until 26 March 2020, all patients with fever, cough 
or dyspnoea and contact with a symptomatic case or 
returning from an active transmission zone (outside 
Portugal) were considered suspect cases and had indi-
cation to be tested. From 26 March, all people with 
fever, onset of cough or dyspnoea, regardless of epi-
demic link, were considered suspect and told by public 
health officials to call the Portuguese NHS Health line 
and were subsequently sent for testing.
Outcomes
We evaluated three primary outcomes: hospitalisa-
tion in the general ward (not ICU), admission to ICU 
and death. Outcomes were considered according to 
data from SINAVEmed, completed as described above. 
Outcome data are registered at the local level, but are 
updated retrospectively at the regional and national 
level (DGS).
Risk factors
From the SINAVEmed dataset, we included the follow-
ing variables: age, sex, chronic diseases/comorbidities 
(asthma, cancer, cardiovascular disease, diabetes (all 
types), immunodeficiencies (including HIV), kidney dis-
ease, liver disease, lung disease (other than asthma), 
haematological disease, chronic neurological disease 
(including dementia)) and region of occurrence of the 
case. Regions were included for adjustment.
Statistical analysis
Descriptive statistics were applied to characterise 
the cohort of confirmed COVID-19 cases and the dis-
tribution by outcomes (Supplementary Material). We 
Table 2
Association between geodemographic factors, comorbidities and intensive care unit admission among COVID-19 cases, 











Crude RR 95% CI p value aRR 95% CI p value
Sex
Women 11,903 88 0.7 Ref.
Men 8,390 173 2.1 2.8 2.2–3.6 < 0.001 2.2 1.7–2.9 < 0.001
Age (years)
0–49 9,675 25 0.3 Ref.
50–59 3,549 40 1.1 4.4 2.7–7.2 0.005 4.5 2.8–7.3 < 0.001
60–69 2,463 67 2.7 10.5 6.7–16.6 < 0.001 8.8 5.6–13.7 < 0.001
70–79 1,808 70 3.9 15.0 9.5–23.6 < 0.001 10.4 6.5–16.6 < 0.001
80–89 1,932 50 2.6 10.0 6.2–16.1 < 0.001 7.3 4.4–12.1 < 0.001
≥ 90 866 9 1.0 4.0 1.9–8.6 0.01 3.8 1.8–8.2 0.001
Region
North 12,207 101 0.8 Ref.
Acores 48 3 6.3 7.6 2.5–23.0 < 0.001 9.3 4.0–22.0 < 0.001
Alentejo 387 9 2.3 2.8 1.4–5.5 0.002 3.2 1.6–6.3 0.001
Algarve 472 18 3.8 4.6 2.8–7.6 < 0.001 5.2 3.2–8.2 < 0.001
Center 2,812 44 1.6 1.9 1.3–2.7 < 0.001 1.8 1.3–2.5 0.001
Lisbon and Tagus Valley 4,264 85 2.0 2.4 1.8–3.2 < 0.001 2.5 1.9–3.3 < 0.001
Madeira 90 0 0.0 0.0 NA 0.386 0.0 0.0–0.0 < 0.001
Comorbidities
Asthma 277 4 1.4 1.1 0.4–3.0 0.814 1.6 0.6–4.4 0.334
Cancer 611 22 3.6 3.0 1.9–4.6 < 0.001 1.1 0.7–1.8 0.549
Cardiovascular disease 54 10 18.5 14.9 8.4–26.5 < 0.001 4.3 2.5–7.4 < 0.001
Diabetes 1,145 53 4.6 4.3 3.1–5.7 < 0.001 1.7 1.3–2.3 0.001
Immunodeficiencies 107 7 6.5 5.2 2.5–10.8 < 0.001 2.8 1.3–5.7 0.006
Kidney disease 400 34 8.5 7.5 5.3–10.5 < 0.001 2.4 1.6–3.7 < 0.001
Liver disease 107 5 4.7 3.7 1.6–8.8 0.002 0.6 0.3–1.7 0.361
Lung disease 688 37 5.4 4.7 3.4–6.6 < 0.001 2.0 1.4–2.9 < 0.001
Haematotological disease 221 8 3.6 2.9 1.4–5.7 0.002 1.1 0.5–2.3 0.823
Neurological disease 794 25 3.2 2.6 1.7–3.9 < 0.001 1.1 0.7–1.7 0.668
aRR: adjusted risk reduction; CI: confidence interval; COVID-19: coronavirus disease; ICU: intensive care unit; NA: not applicable; Ref.: 
reference; RR: risk reduction.
The area under the ROC curve (AUC) was 0.833 (asymptotic 95% CI: 0.811–0.854).
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conducted univariable analysis and calculated absolute 
risks (proportion where each outcome was observed 
by stratum), RR with 95% CI and p values (Wald test). 
We then calculated aRR through multivariable analy-
sis, using Poisson regression models that included the 
same co-variables for each outcome.
Age was divided into six categories with a reference 
group of 0–49 years and groups with increments of 10 
years up to 90 years and above.
Variables with inconclusive or missing data were clas-
sified as follows: for the outcome ICU admission, 
‘unknown’ was considered ‘no’; for death, ’still in 
treatment’ was considered ‘no’ and unknown data for 
death was not included in the analysis. Where avail-
able, these variables were filled as ‘yes’ retrospec-
tively through cross-reference from other sources at 
the national level (real time national digital registry 
of deaths and hospital registries). Both of these out-
comes agreed with aggregated data officially reported 
during the corresponding time period. Missing data for 
other non-mandatory variables like comorbidities were 
assumed ‘no’ because of the notification form archi-
tecture. For admissions to the hospital ward, missing 
outcomes were removed from the analysis. Finally, we 
built forest plots with aRR for the Poisson regression 
and CI for the three clinical outcomes analysed.
To make explicit the assumptions behind variables 
included in the models, we drew a directed acyclic 
graph [15] on the relations between variables and 
potentially biasing pathways considering exposures of 
interest and potential bias (Figure 1).
The regression models were analysed in Stata (version 
14, StataCorp, College Station, Texas, US). All analyses 
used 95% CI and considered a p value < 0.05 as statisti-
cally significant.
Ethical statement
Data were shared by DGS with the National School of 
Public Health–NOVA University of Lisbon under a part-
nership for COVID-19 research. The Ethical Committee 




Of 20,293 laboratory-confirmed cases of COVID-
19, 2,972 (14.6%) were admitted to hospital (gen-
eral ward), 261 (1.3%) were admitted to the ICU and 
502 (2.5%) died. Of the total cases, 41.3% were men, 
58.7% were above 50 years of age and 17.0% had at 
least one recorded comorbidity. Despite having only 
approximately one third of the Portuguese population, 
the North region had 60% of all cases (Supplementary 
Material).
Risk factors for hospitalisation
In the univariable analysis, absolute risk of hospitalisa-
tion increased with age, which was the strongest risk 
factor. Age groups above 60 years of age presented an 
aRR of hospitalisation higher than any chronic disease 
after adjustment, assuming 0–49 years of age as a 
reference.
Different regions had varying hospitalisation risks 
and statistically significant differences in RR that were 
maintained after full adjustment. Comorbidities with 
higher aRR were immunodeficiencies (aRR: 1.8; 95% 
CI: 1.4–2.3), cardiovascular disease (aRR: 1.8; 95% CI: 
1.5–2.2), kidney disease (aRR: 1.6; 95% CI: 1.4–1.7), 
liver disease (aRR: 1.5; 95% CI: 1.2–2.0 and neurologi-
cal disease (aRR 1.8; 95% CI 1.7–2.0) (Table 1).
Risk factors for intensive care unit admission
There was a consistent increase in risk of admission 
to the ICU with increasing age up to 70–79 years (aRR: 
10.4; 95% CI: 6.5–16.6, but reduced in the subsequent 
age groups. These findings were maintained after 
adjustment. As observed for hospitalisation, differ-
ent regions had varying ICU risks and statistically sig-
nificant differences in RR that were maintained after 
adjustment. Among regions with cases in the ICU, the 
North region had the lowest risk. The diseases with 
higher aRR for admission to the ICU were cardiovascu-
lar disease (aRR: 4.3; 95% CI: 2.5–7.4, immunodeficien-
cies (aRR: 2.8; 95% CI: 1.3–5.7), kidney disease (aRR: 
2.4; 95% CI: 1.6–3.7), and lung disease (aRR: 2.0; 95% 
CI: 1.4–2.9). Liver disease and neurological disease 
were associated with hospitalisation but not with ICU 
admission. Age groups above 50 years had higher aRR 
than any chronic disease alone. The adjusted risk of 
admission to the ICU in cases aged 70–79 years was 
more than 10 times the risk of cases aged 0–49 years 
Figure 2
Adjusted risk for hospital (n = 18,670) and intensive care 
unit (n = 20,293) admission among COVID-19 cases using 
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aRR
Hospital ward Intensive care
COVID-19: coronavirus disease.
Reference categories are sex: woman; age: 0–49 years; region: 
North.
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but aRR reduced after 79. Regions maintained small, 
but statistically significant differences after adjust-
ment (Table 2).
A forest plot with a visual representation of aRR and 
95% CI for hospital ward admission and ICU admission 
can be seen in Figure 2.
Risk factors for death
Risk of death was disproportionally affected by age. 
We observed that there was a constant increase of risk 
of death with age, unlike what was seen with hospitali-
sation and ICU admissions. Among cases aged 0–49 
years, the CFR was 0.04%, contrasting with a CFR of 
12.9% among those older than 90 years of age. The 
aRR increased more significantly from the age group 
70–79 years (aRR: 112.7; 95% CI: 41.2–308.5) and 
older. Different regions had slightly different CFRs and 
statistically significant differences of the aRR for three 
regions. The comorbidities with higher aRR were kidney 
(aRR: 2.9; 95% CI: 2.3–3.7), cardiovascular (aRR: 2.6; 
95% CI: 1.7–3.9), and neurological disease (aRR: 2.0; 
95% CI: 1.7–2.5) (Table 3).
A forest plot representing the aRR and 95% CI can be 
seen below in Figure 3. 
Discussion
This study performed during the early stage of the 
COVID-19 pandemic, was designed to identify which 
demographic and clinical factors were associated with 
severe acute outcomes of COVID-19 in the Portuguese 
population, specifically hospitalisation, ICU admis-
sion and death. We used data from all reported cases 
Table 3
Association between geodemographic factors, comorbidities and death among COVID-19 cases, Portugal, 1 March–28 April 











Crude RR 95% CI p value aRR 95% CI p value
Sex
Women 11,900 253 2.1 Ref.
Men 8,370 249 3.0 1.4 1.2–1.7 0 1.4 1.189–1.68 < 0.001
Age (years)
0–49 9,675 4 0.0 Ref.
50–59 3,548 15 0.4 10.2 3.4–30.8 < 0.001 9.8 3.3–29.6 < 0.001
60–69 2,459 44 1.8 43.3 15.6–120.3 < 0.001 37.1 13.3–103.4 < 0.001
70–79 1,800 116 6.4 155.9 57.6–421.8 < 0.001 112.7 41.2–308.5 < 0.001
80–89 1,924 212 11.0 266.5 99.2–715.8 < 0.001 179.1 65.6–489.0 < 0.001
 ≥ 90 864 111 12.9 310.7 114.9–840.5 < 0.001 226.8 82.7–622.1 < 0.001
Regionb
North 12,196 315 2.6 Ref.
Acores 48 0 0.0 0.0 NA 0.259 0.0 0.0–0.0 < 0.001
Alentejo 387 6 1.6 0.6 0.3–1.3 0.205 0.8 0.4–1.8 0.578
Algarve 470 6 1.3 0.5 0.2–1.1 0.077 0.6 0.3–1.4 0.268
Center 2,805 93 3.3 1.3 1.0–1.6 0.031 0.9 0.7–1.1 0.352
Lisbon and Tagus Valley 4,261 74 1.7 0.7 0.5–0.9 0.002 0.7 0.5–0.8 0.001
Madeira 90 0 0.0 0.0 NA 0.122 0.0 0.0–0.0 < 0.001
Comorbidities
Asthma 277 3 1.1 0.4 0.1–1.3 0.133 0.7 0.2–2.2 0.581
Cancer 603 47 7.8 3.4 2.5–4.5 < 0.001 1.3 0.9–1.7 0.151
Cardiovascular disease 53 19 35.8 15.0 10.4–21.7 < 0.001 2.6 1.7–3.9 < 0.001
Diabetes 1,144 83 7.3 3.3 2.6–4.16 < 0.001 1.0 0.8–1.3 0.985
Immunodeficiencies 107 6 5.6 2.3 1.0–5.0 0.037 1.5 0.7–3.3 0.295
Kidney disease 400 98 24.5 12.1 9.9–14.7 < 0.001 2.9 2.3–3.7 < 0.001
Liver disease 107 7 6.5 2.7 1.3–5.5 0.007 0.8 0.4–2.0 0.687
Lung disease 686 60 8.7 3.9 3.0–5.0 < 0.001 1.3 1.0–1.7 0.062
Haematological disease 220 29 13.2 5.6 3.9–7.9 < 0.001 1.2 0.8–1.8 0.3
Neurological disease 790 123 15.6 8.0 6.6–9.7 < 0.001 2.0 1.7–2.5 < 0.001
aRR: adjusted risk reduction; CFR: case fatality rate; CI: confidence interval; COVID-19: coronavirus disease; Ref.: reference; RR: risk 
reduction.
The area under the ROC curve (AUC) was 0.909 (asymptotic 95% CI: 0.900–0.918).
a Data was missing for outcome of death for 23 cases.
b The total for the regions was 20,257 cases; 13 cases were missing.
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during the first 2 months of the epidemic in Portugal 
and have presented RR adjusted for confounding.
We used national epidemiological information 
extracted from the SINAVEmed electronic platform. 
This information was validated by the public health 
authorities network in Portugal at the local, regional 
and national level, which contributed to data quality 
and allowed better population risk estimates in that 
period. Portugal had, at the time, one of the highest 
testing rates per capita, one of the lowest CFR and a 
low test positivity rate in Europe [13,14]. Estimates by 
the London School of Hygiene and Tropical Medicine 
and by the Imperial College London estimated one 
of the lowest under-reporting/under-ascertainment 
in Portugal [11,12]. However, varying levels of under-
ascertainment in different age groups could lead to 
bias in risk estimates. If younger age groups were less 
likely to be diagnosed because they may have milder 
symptoms or symptoms that are not included in test-
ing guidelines, our risk estimates could be under-
estimated for older age groups. It is probable that the 
overall sensitivity of the surveillance system was lower 
before 26 March 2020, as the testing strategy was less 
broad and only symptomatic cases with an epidemic 
link were tested. Some regional differences in testing 
strategies are probably relevant, hence we adjusted for 
this possible confounding.
In this study, we found that increasing age was, as in 
other multivariable analysis [8,10], the most relevant 
risk factor for hospitalisation, ICU admission and 
death [10]. The very high values of aRR for older ages 
(≥ 60 years) in comparison with other risk factors can 
be explained by the very low case fatality observed 
in the reference age group 0–49 years irrespective of 
comorbidities, which are less frequent in this group. 
There is potentially a higher under-estimation in men, 
as with other diseases where health-seeking behaviour 
differs, namely for respiratory symptoms [16]. This, in 
turn, might have led to an overestimation of the risk. 
However, other biological differences may explain part 
of the increased risk in men.
Hospitalisation and ICU admissions had a relevant 
increase in risk in age groups 60–69 and 70–79 years. 
The risk of ICU admission was reduced after 70–79 
years. This is not expected to be due to negative selec-
tion based on age since ICU bed occupation did not 
exceed 60% during that period [17] and there are guide-
lines with criteria for ICU admission in Portugal [18] that 
consider only clinical severity. Other studies found sim-
ilar situations for influenza [19,20]. It is possible that 
some older patients may die without meeting criteria 
for ICU admission. Also, patients who meet those crite-
ria may either die before they can be admitted, or are 
not admitted because they have no expected clinical 
benefit and very low recovery expectations. However, 
further research is needed to understand the benefit of 
ICU treatment among very elderly patients. Debate has 
been ongoing on this topic considering the challenges 
and ethics of admitting very elderly patients to the ICU, 
respecting patient and family wishes and therapeutic 
futility [21-25].
Older age was by far the most important determinant 
for COVID-19-associated death. Most comorbidities 
were associated with increased risk for hospitalisa-
tion, ICU admission and death, especially cardiovas-
cular, kidney, respiratory and neurological disease, 
although risk varied for different outcomes. All comor-
bidities increased risk more homogenously for hospi-
talisation than for ICU admission and death. This could 
be explained by lower thresholds for the decision to 
admit patients to a general ward vs ICU, but also by 
Portuguese guidelines that consider the existence 
of comorbidities for hospital admission but include 
mainly clinical severity criteria for ICU [18]. Risk factors 
for death vary from other outcomes possibly because 
death does not include a clinical management deci-
sion. For ICU admission, the most relevant risk factors 
besides age were cardiovascular disease, immunodefi-
ciencies, kidney disease, and lung disease, while liver, 
neurological and haematological disease were not sig-
nificantly associated.
Asthma was not a risk factor for any outcome, in line 
with what was found in other studies [8,9]. However, 
the largest cohort investigated to date found a slight 
increase in adjusted risk of death for asthma in severe 
cases [10].
Figure 3
Adjusted risk reduction for death among COVID-19 cases 
using a Poisson regression model, Portugal, 1 March–28 
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aAge Risk: 50–59 years (aRR: 9.8; 95% CI: 3.3–29.6); 60–69 years 
(aRR: 37.1; 95% CI: 13.3–103.4); 70–79 years (aRR: 112.7; 95% CI: 
41.2–308.5); 80–89 years (aRR: 9179.1; 95% CI: 65.6–489.0); ≥ 
90 years (aRR: 226.8; 95% CI: 82.7–622.1).
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We found particularly strong associations of older age, 
cardiovascular disease and chronic kidney disease for 
both ICU admission (60–79 years) and death (≥ 60) 
even though risk for ICU reduced in those above 80 
years. A weaker association with chronic lung disease 
was observed, as in a similar study [8], although the 
largest cohort study examining the outcome of death 
with COVID-19 found that lung disease had the highest 
risk among comorbidities [10].
For the outcome of death, our results were similar to the 
International Severe Acute Respiratory and Emerging 
Infection Consortium (ISARIC) study [9] and to the 
OpenSafely Project Cohort [10], although the differ-
ences in risk measures for age were larger. Kidney, car-
diovascular and chronic neurological disease were the 
comorbidities with a stronger association with death. 
Although not specified, most neurological disease is 
expected to be dementia, considering the epidemiol-
ogy of neurological diseases [26].
Regions were included in the models primarily to mini-
mise potential confounding. We found small differ-
ences in the association of region with outcomes after 
adjustment. Since some heterogeneity naturally exists 
between regional epidemic situations, testing strate-
gies and case ascertainment, we hypothesised that 
some of the differences observed between regions 
were primarily due to different testing and case ascer-
tainment, but possibly due to admission practices and 
different treatment quality or access [8]. Significant 
differences in healthcare service response were not 
expected since guidelines with criteria for admission 
to general wards and the ICU have been issued by 
the DGS [18] and capacity was not breached. It is not 
clear if case ascertainment may have been higher in 
the North region. Most cases were reported from this 
region and, while the chance of admission to the ICU 
was lower, the risk of death was higher.
The study has limitations. The extracted data are rou-
tine surveillance data from an early phase of the epi-
demic in Portugal and as such, estimated risks might 
change with increased testing, broadened testing cri-
teria that included a larger spectrum of symptoms, 
higher detection of mild and asymptomatic infection, 
changes in regional incidence and hospital healthcare 
care demand and further data validation. There are also 
other relevant comorbidities that we could not adjust 
for that have been previously found to be of relevance 
for the COVID-19 severity outcomes, such as obesity 
[8-10], economic deprivation [10] and minority ethnic 
groups [10,27]. Hypertension is also not included since 
it was not available in SINAVEmed dataset, although 
recent evidence from the largest cohort to date suggest 
that controlled hypertension alone does not increase 
the risk of death of COVID-19 patients [10]. In our study, 
no data on smoking were available but, as with hyper-
tension, it does not seem to be a relevant factor for 
poorer outcomes [10].
The small numbers observed with cardiovascular dis-
ease are because, contrary to other comorbidities, 
cardiovascular disease is not a specific variable in 
the SINAVEmed notification form. As such, physicians 
must specifically write that condition in the field ‘other 
chronic conditions’ on the form. This may introduce 
information bias as the field ‘other chronic conditions’ 
may be more frequently completed for cases with 
poorer outcomes, overestimating the risk for cardio-
vascular disease. However, other studies conducting 
multivariable analysis from cases have found cardio-
vascular disease to be one of the most relevant risk 
factors [8-10]. People with this and other comorbidities 
such as asthma may also have been more compliant 
with prevention measures.
It is possible that some cases in the dataset could have 
been admitted to the hospital or died after the col-
lected data was made available for research purposes. 
We believe this would not introduce a systematic error 
in risk estimates since this situation is expected to 
be relatively rare considering the large sample size. 
We found no strong reason for those cases to be sig-
nificantly different from those where the outcome had 
already been reported and numbers were coherent with 
officially reported data during that period.
We used aRR in multivariable analysis using Poisson 
regressions assuming constant time of exposure. The 
use of an adjusted odds ratio to estimate an aRR can 
be appropriate for studies of rare outcomes (< 10%) but 
may overestimate the risk if outcomes are more fre-
quent [28-30]. Overestimating RR could inappropriately 
affect clinical decision making, policy development 
and priority setting, as well as economic evaluation 
and targeted prevention programmes or treatments 
[28,29]. Poisson regression is likely to compute confi-
dence intervals that are conservative with more com-
mon outcomes.
We categorised age using 0–49 years as reference 
since other studies conducting multivariable analysis 
have used such age categorisation [9], including the 
largest cohort studied for risk factors for death from 
COVID-19 [10]. Low risk was found in this group for 
acute severe outcomes [8-10].
Our findings aimed to help shape public health policy 
by modelling risk criteria, thereby aiding in prediction 
of healthcare needs in the face of different epidemic 
forecasts. Clinical risk assessment tools could be built 
to aid clinical decisions related to admission to the hos-
pital or ICU, since most patients can be safely followed 
up at home [31]. Policy recommendations and public 
health intervention like vaccination in Portugal and 
other European countries may consider specific comor-
bidities and age cut-offs when defining people at risk. 
As such, it is relevant to understand what level of risk 
is added by each specific characteristic. In Portugal, 
patients with certain comorbidities may be granted 
medically justified absences from work if they cannot 
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work from home [32] and have been prioritised for vac-
cination. Our findings reinforce that if these patients 
become ill with COVID-19, they will be at increased risk 
of hospitalisation, ICU admission and/or death.
Considering absolute risk estimates of specific out-
comes among COVID-19-infected people in different 
age groups or individual risk estimates using models 
parameters, researchers must consider under-ascer-
tainment of mildly symptomatic and asymptomatic 
cases [33]. However, for RR estimates, differential 
under-ascertainment is necessary to introduce bias. 
Under-ascertainment is probably higher in younger 
ages [34] and lower with older age as older people may 
have a lower threshold for testing and have a smaller 
proportion of mild and asymptomatic or paucisymp-
tomatic infections. This could mean modelled RR esti-
mates were underestimated for older patients while 
absolute risk for younger patients was overestimated. 
It will be relevant to revaluate the same data at a later 
time point to examine whether the findings are main-
tained and to generate hypotheses on the reasons 
behind those changes.
This work was one of the references used by the 
Portuguese authorities for initial selection of priority 
groups for vaccination, considering age and combina-
tions of age and relevant comorbidities, with the aim 
of preventing COVID-19-related hospital admissions 
and deaths in the face of initially limited vaccine avail-
ability [35]. Our study adds evidence supporting the 
importance of effective measures specifically targeted 
at protecting older population [36].
Conclusions
Age should be considered as the strongest single risk 
factor for all measured COVID-19 outcomes. This find-
ing should be taken into account both in terms of 
prevention strategies (e.g. public health measures, 
vaccination priorities, healthcare demand scenarios) 
and in terms of clinical management and prognosis. 
Comorbidities also have an impact on clinical out-
comes (especially cardiovascular, kidney, lung disease, 
immunodeficiencies and neurological disease) but the 
associations were weaker than age and varied for dif-
ferent outcomes.
RR had larger increases after 60 years of age for the 
outcome death, as CFR was low in those aged 49 years 
and under. Comprehensive epidemiological surveil-
lance of settings with a high risk population, including 
long-term care facilities, and prevention and control 
measures to protect the older population and those 
around them are part of an efficient strategy to reduce 
hospital admission and deaths. In addition, a strong 
and innovative communication plan targeted to the 
public to protect older people should be pursued.
Risk-stratified public health measures should primar-
ily consider age but individual preventive behaviours 
should be promoted across all age groups to reduce 
overall spread and ultimately prevent infection in 
higher risk groups. However, strategies aimed at pro-
tecting ‘only’ those at higher risk might end up being 
inefficient, impractical or unethical [37]. Moreover, 
other negative long-term effects of the disease on 
health among lower risk groups are still uncertain and 
could have a relevant future impact [38]. These include 
COVID-19-associated syndromes and conditions.
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